Suppr超能文献

杂环 P2Y 受体拮抗剂的构效关系:用哌啶生物等排体去除两性离子特征。

Structure-Activity Relationship of Heterocyclic P2Y Receptor Antagonists: Removal of the Zwitterionic Character with Piperidine Bioisosteres.

机构信息

Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, United States.

Random Walk Ventures, LLC, 108 Lincoln Street Unit 6B, Boston, Massachusetts 02111, United States.

出版信息

J Med Chem. 2021 Apr 22;64(8):5099-5122. doi: 10.1021/acs.jmedchem.1c00164. Epub 2021 Mar 31.

Abstract

A known zwitterionic, heterocyclic P2YR antagonist was substituted with diverse groups on the central phenyl and terminal piperidine moieties, following a computational selection process. The most potent analogues contained an uncharged piperidine bioisostere, prescreened in silico, while an aza-scan (central phenyl ring) reduced P2YR affinity. Piperidine amide , 3-aminopropynyl , and 5-(hydroxymethyl)isoxazol-3-yl) congeners in the triazole series maintained moderate receptor affinity. Adaption of 5-(hydroxymethyl)isoxazol-3-yl gave the most potent naphthalene-containing (; MRS4654; IC, 15 nM) and less active phenylamide-containing () scaffolds. Thus, a zwitterion was nonessential for receptor binding, and molecular docking and dynamics probed the hydroxymethylisoxazole interaction with extracellular loops. Also, amidomethyl ester prodrugs were explored to reversibly block the conserved carboxylate group to provide neutral analogues, which were cleavable by liver esterase, and in vivo efficacy demonstrated. We have, in stages, converted zwitterionic antagonists into neutral molecules designed to produce potent P2YR antagonists for in vivo application.

摘要

一种已知的两性离子、杂环 P2YR 拮抗剂,在计算选择过程之后,在中心苯基和末端哌啶部分上用各种基团取代。最有效的类似物含有未带电的哌啶生物等排体,这是在计算机筛选之前预先筛选的,而氮杂扫描(中心苯基环)降低了 P2YR 亲和力。在三唑系列中,哌啶酰胺、3-氨基丙炔基和 5-(羟甲基)异噁唑-3-基同系物保持中等受体亲和力。对 5-(羟甲基)异噁唑-3-基的适应使最有效的含萘(; MRS4654; IC,15 nM)和活性较低的含苯甲酰胺的支架得以实现。因此,两性离子对于受体结合并非必不可少,分子对接和动力学探测了羟甲基异噁唑与细胞外环的相互作用。此外,还探索了氨甲基酯前药以可逆地阻断保守的羧酸盐基团,提供中性类似物,这些类似物可被肝酯酶切割,体内功效得到了证明。我们已经分阶段地将两性离子拮抗剂转化为中性分子,旨在产生用于体内应用的强效 P2YR 拮抗剂。

相似文献

4
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y Receptor.基于结构的 P2Y 受体杂环拮抗剂的修饰。
J Med Chem. 2018 Jun 14;61(11):4860-4882. doi: 10.1021/acs.jmedchem.8b00168. Epub 2018 May 16.
8
Recent progress on the discovery of P2Y receptor antagonists.新型 P2Y 受体拮抗剂的研究进展。
Eur J Med Chem. 2019 Aug 1;175:34-39. doi: 10.1016/j.ejmech.2019.04.068. Epub 2019 Apr 29.

引用本文的文献

1
Drug-like Antagonists of P2Y Receptor Subtypes: An Update.P2Y 受体亚型的类药拮抗剂:最新进展
J Med Chem. 2025 May 8;68(9):9057-9083. doi: 10.1021/acs.jmedchem.5c00249. Epub 2025 Apr 27.
9
10
Purinergic Signaling in Liver Pathophysiology.嘌呤能信号在肝脏病理生理学中的作用。
Front Endocrinol (Lausanne). 2021 Aug 11;12:718429. doi: 10.3389/fendo.2021.718429. eCollection 2021.

本文引用的文献

4
P2Y Receptor Antagonists Reverse Chronic Neuropathic Pain in a Mouse Model.P2Y受体拮抗剂可逆转小鼠模型中的慢性神经性疼痛。
ACS Med Chem Lett. 2020 Apr 30;11(6):1281-1286. doi: 10.1021/acsmedchemlett.0c00115. eCollection 2020 Jun 11.
5
Physicochemical Properties of Zwitterionic Drugs in Therapy.治疗用两性离子药物的物理化学性质。
ChemMedChem. 2020 Jul 3;15(13):1102-1110. doi: 10.1002/cmdc.202000164. Epub 2020 Jun 9.
8
Update of P2Y receptor pharmacology: IUPHAR Review 27.P2Y受体药理学更新:IUPHAR综述27
Br J Pharmacol. 2020 Jun;177(11):2413-2433. doi: 10.1111/bph.15005. Epub 2020 Apr 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验